GlobeNewsWire
28 May 2026, 12:50 UTC · 16w ago
Verdict
Headline takes no side. We score ENTX +0.80 across three claims — strongly bullish.
+0.80strongly bullish
More positive than 83% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Entera Bio's EB613 oral tablet has been selected as the final candidate for a planned Phase 3 study in postmenopausal women with osteoporosis.
More positive than 91% of claims this week
New clinical data for EB613 will be presented as a 'Late Breaking Oral Presentation' at the ENDO 2026 Annual Meeting.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More positive than 75% of claims this week
Entera is presenting pre-clinical data on EB612 for hypoparathyroidism and PK-PD study results for EB618 (a dual GLP-1/Glucagon receptor agonist) for obesity.
More positive than 62% of claims this week
Which stocks this story touches
More positive than 83% of ticker scores this week
Company announced multiple pipeline abstracts accepted for presentation and a late-breaking oral presentation for its lead osteoporosis candidate.
More positive than 53% of ticker scores this week
Mentioned as a collaborator on the development of an oral GLP-2 tablet.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The Motley Fool
3d ago
+148.7%
Price agrees with the score
$2.96 vs $1.19 close before publication (May 27) · not market-adjusted
ENTX chart →
